WraSer Pharmaceuticals
http://www.wraser.com/default.asp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WraSer Pharmaceuticals
Deal Watch: Tourmaline Will Pursue Its Thyroid Eye Disease Ambitions Following Merger With Talaris
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.
Malaria The Main Focus Of New GHIT Fund Allocations
Japan's GHIT Fund is making new investments in a slew of pipeline projects for malaria, tuberculosis, leishmaniasis and dengue that involve local pharma industry and other academic partners.
Davinder Gill On Researching Low-Cost Vaccines: An Interview With PharmAsia News (Part 2 of 2)
Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Services
- Group Purchasing
- Home Infusion
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice